Browse DUSP22

Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF00782 Dual specificity phosphatase
Function

Activates the Jnk signaling pathway. Dephosphorylates and deactivates p38 and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) (By similarity).

> Gene Ontology
 
Biological Process GO:0000188 inactivation of MAPK activity
GO:0001933 negative regulation of protein phosphorylation
GO:0002250 adaptive immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002710 negative regulation of T cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0006469 negative regulation of protein kinase activity
GO:0006470 protein dephosphorylation
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007254 JNK cascade
GO:0016311 dephosphorylation
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0031098 stress-activated protein kinase signaling cascade
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0033673 negative regulation of kinase activity
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0042110 T cell activation
GO:0042326 negative regulation of phosphorylation
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0043410 positive regulation of MAPK cascade
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0050777 negative regulation of immune response
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050854 regulation of antigen receptor-mediated signaling pathway
GO:0050856 regulation of T cell receptor signaling pathway
GO:0050858 negative regulation of antigen receptor-mediated signaling pathway
GO:0050860 negative regulation of T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051348 negative regulation of transferase activity
GO:0051403 stress-activated MAPK cascade
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071593 lymphocyte aggregation
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:1902532 negative regulation of intracellular signal transduction
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004725 protein tyrosine phosphatase activity
GO:0008138 protein tyrosine/serine/threonine phosphatase activity
GO:0016791 phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DUSP22 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DUSP22 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DUSP22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6780.028
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0640.615
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3960.8
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2310.329
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2860.893
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1640.953
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0230.942
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3350.841
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3350.859
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.10.943
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6570.745
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0720.385
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DUSP22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DUSP22. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DUSP22. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DUSP22.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DUSP22. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DUSP22 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DUSP22 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDUSP22
Namedual specificity phosphatase 22
Aliases JSP1; JKAP; VHX; JSP-1; LMW-DSP2; LMWDSP2; JNK-stimulating phosphatase 1; JNK-stimulatory phosphatase-1; MAP ......
Chromosomal Location6p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DUSP22 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.